NICE Rejects New MS Pill as too Expensive

NICE Rejects New MS Pill as too Expensive

Assessment

Interactive Video

Chemistry, Health Sciences, Biology

University

Hard

Created by

Quizizz Content

FREE Resource

Amanda Kirk's life improved with fingolimod, a drug for MS, but NICE deemed it not cost-effective, impacting many patients. The MS Society opposes this decision, fearing it will leave thousands without necessary treatment. Amanda's treatment is secure until December, after which private payment may be required.

Read more

2 questions

Show all answers

1.

OPEN ENDED QUESTION

3 mins • 1 pt

What are the potential consequences of the decision on patients currently using fingolimod?

Evaluate responses using AI:

OFF

2.

OPEN ENDED QUESTION

3 mins • 1 pt

What does Amanda Kirk plan to do after her treatment coverage ends?

Evaluate responses using AI:

OFF